Introduction

De Sanctis-Cacchione (DSC) syndrome is one of the rarest, most severe variants of xeroderma pigmentosum (XP).¹ The Patient presents with skin and ocular manifestations accompanied by neurological abnormalities, short stature(dwarfism), intellectual disabilities, and underdevelopment of testes and ovaries(hypogonadism). Low intelligence, an abnormally small head (microcephaly), loss of control over voluntary movement (ataxia), and/or no (areflexia) or weakened (hyporeflexia) reflexes are the most prevalent types of neurological abnormalities with De Sanctis-Cacchione syndrome. Because it shares resembling symptoms with several other pregnoid and neurocutaneous syndromes, clinicians often face significant challenges. Clear differentiation is essential for patient management, genetic counselling and proper treatment. 

Overview of de sanctis-cacchione syndrome

Etiology and genetic basis

It is caused by gene mutations that mediate nucleotide excision repair (NER), and are most frequently associated with xeroderma pigmentosum (XP) complementation groups. Failure to repair UV-induced DNA damage results in cutaneous malignancies as well as progressive neurodegeneration

Key clinical feature

• Skin: hypopigmentation, hyperpigmentation, photosensitivity, dry skin, along with poikiloderma
• Head and Face: Microcephaly (small head circumference), a wizen face, deep-set eyes, mandible prognathism, and malformed ears
• Neurological: Mental retardation with intellectual disability, peripheral neuropathy, impaired vision, hearing, and speech, along with ataxia(compromised coordination)  and choreoathetosis (involuntary movements)
• Growth and Development: Usually Short stature(dwarfism)
• Hypogonadism and sensorineural deafness

Pathophysiology

DSc results in severe impairment of the nucleotide excision repair (NER) pathway, which deals with the repair of large DNA damage induced by ultraviolet (UV) radiation. Mutations in genes involved in xeroderma pigmentosum (XP)-related pathways cause an individual to lack the ability to repair UV-caused DNA damage, which causes accumulation of unrepaired lesions in both proliferating and non-dividing cells of the individual.

 In the skin, this abnormality presents as photo-hyperirritability, early pigment alterations, and a significantly heightened frequency of malignancy by the survival of mutagenic DNA damage that mediates carcinogenesis. The build-up of unrepaired DNA in the central nervous system, where the neurons lack the ability to divide to dilute the damage, disrupts transcription, cellular homeostasis, and ultimately leads to apoptosis, causing progressive microcephaly, intellectual disability, spasticity, and ataxia. The systemic effects of defective DNA repair manifest in growth retardation, developmental delay, and endocrine abnormalities, including hypogonadism. Therefore, genomic instability is the unifying pathophysiological basis of DSCS and the cause of the three hallmarks of severe neurodegeneration, growth retardation, and cutaneous malignancies, which manifest at an early age.

Overview of related syndromes

Progeroid syndromes

• Hutchinson-Gilford Progeria Syndrome (HGPS): This is a growth retardation disorder, alopecia, scleroderma-like skin, and heart disease caused by mutations in LMNA
• Werner Syndrome: Early puberty onset with accelerated ageing, cataracts, diabetes, osteoporosis, and risk of increased malignancy
• Cockayne Syndrome: growth retardation, photosensitivity, microcephaly, progressive neurological impairment, and sensorineural hearing loss associated with mutations in ERCC6 or ERCC8

Neurocutaneous syndromes

• Tuberous Sclerosis Complex (TSC): A non-progressive condition of the brain, kidneys, and heart resulting in a benign hamartoma due to mutation of either TSC1 or TSC2
• Neurofibromatosis Type 1 (NF1): Cutaneous and plexiform neurofibromas, cafe-au-lait macules, optic pathway gliomas, and learning disabilities
• Ataxia Telangiectasia: ATM gene defects are associated with progressive cerebellar ataxia, oculocutaneous telangiectasias, immunodeficiency, and predisposition to lymphoid malignancies

Key differentiating features

Diagnostic approaches

• Clinical Evaluation and Family History
  In DSCS, the combination of severe photosensitivity, early-onset cutaneous malignancies, and progressive neurological impairment provides strong diagnostic clues. Associated systemic findings such as growth failure, hypogonadism, and microcephaly further strengthen the suspicion. Family history, especially consanguinity or siblings with similar features, is valuable in identifying hereditary DNA repair disorders. Importantly, clinicians must distinguish DSCS from conditions like Cockayne syndrome, where photosensitivity occurs without cancer predisposition, or Hutchinson-Gilford progeria, where premature aging features dominate but UV sensitivity is absent.
• Genetic testing (e.g., nucleotide excision repair pathway mutations in DSCS)
  Genetic tests are involved in the definitive diagnosis of De Sanctis-Cacchione Syndrome (DSCS), the most severe form of xeroderma pigmentosum (XP).DSCS is extremely sensitive to the sun, develops malignancies of the skin at an early age, and undergoes gradual progressive neurological impairment, all secondary to defects in the nucleotide excision repair (NER) pathway that repairs UV-induced DNA damage. Mutations in genes like ERCC6 (CSB), XPA, ERCC2 (XPD), and XPC have been identified in DSCS  patients.

How genetic testing works

1. Underlying Defect: DSCS arises from impaired DNA repair due to mutations in NER pathway genes
2. Complementation Groups: Historically, patient cells were hybridised with XP cells to identify the defective gene group
3. Modern Sequencing: Next-generation sequencing (NGS) or targeted gene panels now directly identify mutations

• Imaging (MRI for neurocutaneous syndromes)

Neurological degeneration, such as cerebral and cerebellar atrophy, microcephaly, and intellectual disability, is typically demonstrated by imaging studies in De Sanctis-Cacchione syndrome (a form of xeroderma pigmentosum with neurological features). Diffuse brain atrophy has been shown by Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) scans, and dysmyelination and ventriculomegaly may be present. Other results might include basal ganglia calcification, sensorineural hearing loss, and optic atrophy.

Management of  de sanctis-cacchione syndrome

De Sanctis-Cacchione syndrome (DSCS) is a rare, inherited disorder with no cure. Management is symptomatic and supportive, and it requires a comprehensive, multidisciplinary approach to address the syndrome's characteristic neurological, cutaneous, and ophthalmic issues.Skin and Eye Management:

•  Sun protection: Rigorous protection from ultraviolet (UV) light to prevent skin damage and cancer
•  Limit outdoor activities during daylight hours 
• Wear protective clothing, including wide-brimmed hats, gloves, and long sleeves
• Use broad-spectrum topical sunscreens with a high sun protection factor (SPF)
• Wear UV-absorbing sunglasses to protect the eyes
•  Install UV protective film on windows at home and in vehicles
• Avoid or minimize exposure to fluorescent and halogen lights
• Periodic tests: Dermatological and eye tests are to be conducted every 3 to 6 months for the  screening of  new lesions

Treatment of skin lesions: for precancerous or cancerous skin lesions, the treatment algorithm may include:

• Cryotherapy: Using extreme cold, often liquid nitrogen, to freeze and destroy cancerous or precancerous cells
• Topical agents: Chemotherapeutic agents like 5-fluorouracil or immunomodulators like imiquimod
• Oral retinoids: Low-dose isotretinoin can be used for chemoprevention to reduce the formation of new skin cancers
• Surgery: Surgical excision or Mohs 

FAQs

Q.1 At what age do symptoms of de sanctis-cacchione syndrome usually appear?

Most children show signs in early infancy or toddler years, with extreme sun sensitivity, developmental delay, and neurological abnormalities becoming noticeable within the first few years of life.

Q.2 Can lifestyle changes make a difference in DSCS management?

Yes. Avoiding sun exposure, wearing UV-blocking clothing, and using sunscreen consistently can significantly delay skin damage and cancer development.

Q.3 Is genetic counselling recommended for families?

Absolutely. Since DSCS is inherited in an autosomal recessive pattern, genetic counseling helps families understand risks for future pregnancies and explore prenatal or carrier testing.

Q.4 What supportive therapies improve quality of life?

Physical therapy, speech therapy, developmental support, and regular dermatological and neurological care can improve daily functioning and delay complications.

Summary

The most severe and rare type of xeroderma pigmentosum (XP) is called De Sanctis-Cacchione Syndrome (DSCS), which occurs as a result of mutations in genes of the nucleotide excision repair (NER) pathway that negatively impact DNA repair, causing extreme photosensitivity, skin cancer at an early stage, progressive neurological disease, growth retardation, and hypogonadism. Due to the overlapping of the conditions with other syndromes and disorders like progeroid and neurocutaneous syndromes, including Hutchinson-Gilford Progeria, Cockayne Syndrome, Tuberous Sclerosis, Neurofibromatosis Type 1, and Ataxia Telangiectasia, distinguishing between the conditions is clinically difficult but essential in order to diagnose, prognose, and genetically counsel the disorder.

Diagnosis is made by clinical findings, family history, genetic testing to prove the presence of NER mutations, and imaging proving the presence of cerebral and cerebellar atrophy or dysmyelination. The management is still supportive with a strict focus on photoprotection and dermatological surveillance with treatment of precancerous lesions, malignant lesions, and neurological and developmental support using therapies and genetic counselling of families. Even though there is no curative treatment, early diagnosis and a multidisciplinary approach may dramatically increase the quality of life, and continued efforts into gene repair and molecular therapy provide the future.